Kane Biotech Inc.
KNBIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.94 | 0.14 | -0.21 |
| FCF Yield | -28.34% | -28.43% | -31.93% | -15.01% |
| EV / EBITDA | -4.49 | -6.14 | -5.28 | -4.99 |
| Quality | ||||
| ROIC | -508.01% | -179.47% | -97.00% | -124.17% |
| Gross Margin | 41.91% | 73.48% | 52.96% | 35.36% |
| Cash Conversion Ratio | -0.67 | 0.64 | 0.80 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.95% | -54.75% | 25.76% | -1.72% |
| Free Cash Flow Growth | -30.04% | -3.19% | -18.48% | 34.99% |
| Safety | ||||
| Net Debt / EBITDA | -0.49 | -2.63 | -1.95 | -0.84 |
| Interest Coverage | -7.19 | -2.76 | -4.23 | -11.74 |
| Efficiency | ||||
| Inventory Turnover | 3.21 | 0.16 | 1.64 | 2.00 |
| Cash Conversion Cycle | -229.16 | -1,714.12 | 191.36 | 205.54 |